X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with Dishman Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs DISHMAN PHARMA - Comparison Results

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES DISHMAN PHARMA VENUS REMEDIES/
DISHMAN PHARMA
 
P/E (TTM) x -9.2 25.1 - View Chart
P/BV x 0.1 3.3 4.3% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 VENUS REMEDIES   DISHMAN PHARMA
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-17
DISHMAN PHARMA
Mar-16
VENUS REMEDIES/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs143374 38.1%   
Low Rs65129 50.4%   
Sales per share (Unadj.) Rs324.2197.8 163.9%  
Earnings per share (Unadj.) Rs6.421.2 30.2%  
Cash flow per share (Unadj.) Rs40.634.7 116.9%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs366.0179.9 203.4%  
Shares outstanding (eoy) m12.3480.69 15.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.31.3 25.2%   
Avg P/E ratio x16.211.9 136.6%  
P/CF ratio (eoy) x2.67.2 35.3%  
Price / Book Value ratio x0.31.4 20.3%  
Dividend payout %09.4 0.0%   
Avg Mkt Cap Rs m1,28220,306 6.3%   
No. of employees `0000.90.8 108.9%   
Total wages/salary Rs m2515,355 4.7%   
Avg. sales/employee Rs Th4,430.119,252.7 23.0%   
Avg. wages/employee Rs Th278.06,459.5 4.3%   
Avg. net profit/employee Rs Th87.62,064.1 4.2%   
INCOME DATA
Net Sales Rs m4,00015,961 25.1%  
Other income Rs m23265 8.6%   
Total revenues Rs m4,02316,226 24.8%   
Gross profit Rs m7854,103 19.1%  
Depreciation Rs m4221,091 38.7%   
Interest Rs m344944 36.4%   
Profit before tax Rs m422,334 1.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-37624 -5.9%   
Profit after tax Rs m791,711 4.6%  
Gross profit margin %19.625.7 76.3%  
Effective tax rate %-87.926.7 -328.9%   
Net profit margin %2.010.7 18.4%  
BALANCE SHEET DATA
Current assets Rs m2,60611,018 23.7%   
Current liabilities Rs m1,9809,517 20.8%   
Net working cap to sales %15.69.4 166.4%  
Current ratio x1.31.2 113.7%  
Inventory Days Days128110 116.1%  
Debtors Days Days4335 123.9%  
Net fixed assets Rs m5,35316,304 32.8%   
Share capital Rs m123161 76.5%   
"Free" reserves Rs m4,39312,907 34.0%   
Net worth Rs m4,51614,516 31.1%   
Long term debt Rs m1,6184,189 38.6%   
Total assets Rs m8,29129,805 27.8%  
Interest coverage x1.13.5 32.3%   
Debt to equity ratio x0.40.3 124.2%  
Sales to assets ratio x0.50.5 90.1%   
Return on assets %5.18.9 57.2%  
Return on equity %1.811.8 14.9%  
Return on capital %6.317.5 35.9%  
Exports to sales %024.8 0.0%   
Imports to sales %18.43.7 492.7%   
Exports (fob) Rs mNA3,956 0.0%   
Imports (cif) Rs m736596 123.5%   
Fx inflow Rs m04,952 0.0%   
Fx outflow Rs m736697 105.7%   
Net fx Rs m-7364,255 -17.3%   
CASH FLOW
From Operations Rs m9972,786 35.8%  
From Investments Rs m-461-1,529 30.2%  
From Financial Activity Rs m-571-941 60.7%  
Net Cashflow Rs m-35316 -11.1%  

Share Holding

Indian Promoters % 32.9 61.4 53.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 3.7 4.9%  
FIIs % 0.6 12.7 4.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 22.1 300.5%  
Shareholders   20,121 46,261 43.5%  
Pledged promoter(s) holding % 36.4 35.8 101.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   DR. REDDYS LAB  IPCA LABS  ASTRAZENECA PHARMA  AUROBINDO PHARMA  PIRAMAL ENTERPRISES  

Compare VENUS REMEDIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Rising Oil Prices; RBI Minutes and Top Stocks in Action Today(Pre-Open)

Indian share markets surged on Wednesday, snapping a two-day losing streak led by gains Reliance Industries and bank stocks.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (4QFY18); Net Profit Down 307.2%

Jun 12, 2018 | Updated on Jun 12, 2018

For the quarter ended March 2018, VENUS REMEDIES has posted a net profit of Rs 94 m (down 307.2% YoY). Sales on the other hand came in at Rs 932 m (up 16.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Jun 20, 2018 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 8-QTR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS